iShares S&P GSCI Commodity-Indexed Trust ETF vs Nuvation Bio Inc. Class A Common Stock — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.08 (market cap $1.02B), while Nuvation Bio Inc. Class A Common Stock trades at $5 (market cap $1.74B). The key difference: Nuvation Bio Inc. Class A Common Stock is the larger of the two by market cap, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| GSG | NUVB | |
|---|---|---|
Market Cap | $1.02B | $1.74B |
Volume | 1,256,221 | 9,289,619 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $9.54 |
52-Week Low | $22.45 | $3.41 |
Typical Hold Time | 40 Days | 1 Days |
Enterprise Value | — | $1.33B |
Signals from Pluang's Aura AI — not financial advice
GSG trades at $36.08, up 1.23% with neutral technical signals. The company reported strong 2024 results with $51.25M revenue and $69.99M net income, though cash flow turned negative at -$932.80K. Assets remain robust at $968.15M with minimal debt, while recent news highlights commodity market volatility and energy sector exposure as key drivers.
Outlook remains cautious due to commodity price sensitivity and geopolitical risks, though strong profitability and clean balance sheet provide stability. Analyst sentiment is mixed with neutral ratings prevailing, suggesting limited near-term catalysts beyond broader commodity trends.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →